ADC Therapeutics (NYSE:ADCT) Receives "Outperform" Rating from Royal Bank Of Canada

Key Points

• Royal Bank of Canada reissued an "Outperform" rating with a $6.00 price target (about a 59.4% upside vs. the prior close), while consensus sentiment is a "Moderate Buy" with an average target of $8.00 and three analysts rated the stock Buy vs. one Sell.
• ADC has near-term binary catalysts—LOTIS-5 Phase 3 topline expected Q2 2026 with full LOTIS-5 and LOTIS-7 readouts by year-end—and reported Q1 net product revenue of ~$20.8M and cash of ~$231M, which the company says provides runway into 2028.
• Q1 results showed an EPS miss (loss of $0.21 vs. consensus -$0.19) despite a revenue beat, and significant insider selling occurred (Redmile sold 2.63M shares; insiders sold 5.88M shares in the last three months).

ADC Therapeutics (NYSE:ADCT - Get Free Report)'s stock had its "outperform" rating reissued by Royal Bank Of Canada in a report released on Tuesday,Benzinga reports. They currently have a $6.00 price objective on the stock. Royal Bank Of Canada's price objective would indicate a potential upside of 59.40% from the stock's previous close.

Other equities research analysts have also issued reports about the stock. Weiss Ratings restated a "sell (d-)" rating on shares of ADC Therapeutics in a report on Monday, April 20th. HC Wainwright restated a "buy" rating and issued a $8.00 price objective on shares of ADC Therapeutics in a report on Tuesday. Three equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, ADC Therapeutics currently has an average rating of "Moderate Buy" and a consensus target price of $8.00.

ADC Therapeutics Stock Performance

ADC Therapeutics stock traded up $0.08 during mid-day trading on Tuesday, hitting $3.76. 328,842 shares of the company traded hands, compared to its average volume of 850,343. ADC Therapeutics has a one year low of $1.23 and a one year high of $4.98. The stock has a market cap of $478.74 million, a price-to-earnings ratio of -3.15 and a beta of 1.83. The stock has a fifty day moving average price of $4.04 and a 200-day moving average price of $3.96.

ADC Therapeutics (NYSE:ADCT - Get Free Report) last announced its earnings results on Monday, May 4th. The company reported ($0.21) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.19) by ($0.02). The business had revenue of $20.85 million for the quarter, compared to analyst estimates of $19.99 million. During the same period in the previous year, the firm posted ($0.36) EPS. Sell-side analysts predict that ADC Therapeutics will post -0.82 EPS for the current year.

Insider Buying and Selling at ADC Therapeutics

In other news, major shareholder Redmile Group, Llc sold 2,634,506 shares of the business's stock in a transaction that occurred on Thursday, April 2nd. The shares were sold at an average price of $3.28, for a total value of $8,641,179.68. Following the completion of the sale, the insider directly owned 12,666,731 shares in the company, valued at approximately $41,546,877.68. The trade was a 17.22% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In the last three months, insiders have sold 5,880,415 shares of company stock valued at $19,641,067. Insiders own 5.40% of the company's stock.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in ADCT. R Squared Ltd purchased a new position in shares of ADC Therapeutics in the first quarter worth $38,000. Engineers Gate Manager LP purchased a new position in shares of ADC Therapeutics in the fourth quarter worth $43,000. ProShare Advisors LLC increased its stake in shares of ADC Therapeutics by 27.0% in the fourth quarter. ProShare Advisors LLC now owns 15,727 shares of the company's stock worth $56,000 after buying an additional 3,339 shares during the period. AXQ Capital LP purchased a new position in shares of ADC Therapeutics in the fourth quarter worth $57,000. Finally, Henrickson Nauta Wealth Advisors Inc. purchased a new position in shares of ADC Therapeutics in the fourth quarter worth $69,000. 41.10% of the stock is owned by hedge funds and other institutional investors.

Key ADC Therapeutics News

Here are the key news stories impacting ADC Therapeutics this week:

• Positive Sentiment: HC Wainwright reaffirmed a "buy" rating and set an $8.00 price target (roughly +112% upside vs. current levels), which can attract demand from growth-oriented investors and supports higher valuation expectations. Benzinga
• Positive Sentiment: Company reiterated near-term clinical catalysts: LOTIS-5 Phase 3 topline data expected in Q2 2026, with full data for LOTIS-5 and LOTIS-7 anticipated by year-end — clear potential binary catalysts that could move the stock on positive or negative readouts. PR Newswire: Q1 2026 Results & Operational Updates
• Positive Sentiment: Q1 reported net product revenue of about $20.0M and cash & equivalents of $231M with an expected runway at least into 2028 — this reduces near-term financing risk and supports commercial execution through upcoming readouts. PR Newswire: Q1 2026 Results & Operational Updates
• Neutral Sentiment: Management held an earnings conference call and published slide materials — useful for detail on commercial uptake, spend cadence and timelines but not immediately catalytic absent new guidance. Q1 Slide Deck / Press Release
• Neutral Sentiment: Earnings call transcripts are available for those wanting management color on commercial trends and the timing/details for the LOTIS programs. These are informational but unlikely to move the stock by themselves. Yahoo Finance: Q4/Q1 Transcripts
• Negative Sentiment: Q1 EPS missed consensus: reported loss of $0.21 vs. consensus -$0.19 (though an improvement vs. prior year -$0.36). The EPS miss could temper enthusiasm until clinical readouts validate growth expectations. Zacks: Q1 Loss, Beats Revenue Estimates

ADC Therapeutics Company Profile

ADC Therapeutics SA is a clinical-stage biopharmaceutical company focused on the discovery and development of highly targeted antibody-drug conjugates (ADCs) designed to treat hematological malignancies such as non-Hodgkin lymphoma and acute myeloid leukemia. By marrying the specificity of monoclonal antibodies with potent cytotoxic payloads, the company aims to maximize tumor cell eradication while limiting off-target toxicity.

At the core of ADC Therapeutics' portfolio is loncastuximab tesirine-lpyl, a CD19-directed ADC that received accelerated approval from the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.